As the popularity of GLP-1 meds like Wegovy and Zepbound grows, fewer Americans are turning to weight-loss surgeries to trim their waistlines, a new report finds.

Study of those who started taking blockbuster weight loss drugs in 2021 suggests patients need support services, not just the medications.

The findings spell an uncertain future for hospitals and clinics that derive a significant portion of their revenues from obesity procedures.

After insurance for New York City employees began covering GLP-1 weight-loss injectables, more than 1,000 city workers and their dependents began using the drugs — and now, they're being told that coverage was accidental.

Prescriptions of this GLP-1 class of diabetes and weight-loss medications more than doubled between 2022 and 2023, a new tally finds. "In contrast, there was a 25.6% decrease in patients undergoing metabolic bariatric surgery" during the same time period,

Meds like Wegovy are all over the news. But are they right for you, especially if you're older than the average user?By Hallie LevineAre you wondering whether you’re a candidate for one of the